Glycyl-L-Prolyl-L-Glutamate Pseudotripeptides for Treatment of Alzheimer’s Disease

Hasan Turkez 1,*, Ivana Cacciatore 2, Lisa Marinelli 2, Erika Fornasari 2, Mehmet Enes Aslan 3, Kenan Cadirci 4, Cigdem Yuce Kahraman 5, Özge Caglar 3, Abdulgani Tatar 5, Giuseppe Di Biase 2, Ahmet Hacimuftuoglu 6, Antonio Di Stefano 2 and Adil Mardinoglu 7,8,*

Abstract: So far, there is no effective disease-modifying therapies for Alzheimer’s Disease (AD) in clinical practice. In this context, glycine-L-proline-L-glutamate (GPE) and its analogs may open the way for developing a novel molecule for treating neurodegenerative disorders, including AD. In turn, this study was aimed to investigate the neuroprotective potentials exerted by three novel GPE peptidomimetics (GPE1, GPE2, and GPE3) using an in vitro AD model. Anti-Alzheimer potentials were determined using a wide array of techniques, such as measurements of mitochondrial viability (MTT), and lactate dehydrogenase (LDH) release assays, determination of acetycholinesterase (AChE), α-secretase and β-secretase activities, comparisons of total antioxidant capacity (TAC) and total oxidative status (TOS) levels, flow cytometric and microscopic detection of apoptotic and necrotic neuronal death, and investigating gene expression responses via PCR arrays involving 64 critical genes related to 10 different pathways. Our analysis showed that GPE peptidomimetics modulate oxidative stress, ACh depletion, α-secretase inactivation, apoptotic, and necrotic cell death. In vitro results suggested that treatments with novel GPE analogs might be promising therapeutic agents for treatment and/or or prevention of AD.

Keywords: Alzheimer’s disease; neurotoxicity; glycine-proline-glutamate peptidomimetics; in vitro cell culture model; gene expressions

1. Introduction

The glycine-L-proline-L-glutamate (GPE) (Figure 1) is a naturally cleaved N-terminal tripeptide of IGF-1 via brain proteases. It is commercially available as Glypromate [1,2]. GPE executes remarkable neuroprotective properties in several in vitro and in vivo models, demonstrating its involvement in traumatic brain injury and chronic neurodegeneration [3–9]. Literature showed that GPE treatment has a positive impact on the proliferation and migration of mouse neural stem cells (NSCs) by altering extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase PI3K-Akt pathways associated with neuroprotective activity [10]. Additionally, amyloid-beta (Aβ) peptide is believed to induce ROS’s excessive formation via the mechanism requiring NMDA receptor activation on hippocampal...
neuronal cultures. At this point, GPE has been shown to have a binding affinity toward NMDA receptors, but not to other ionotropic glutamate subfamilies, such as (2S)-2-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) or kainate (KA) receptors. Hence, GPE is proposed to be a potential target for rational design of neuroprotective agents for neurological disorders [10]. Interestingly, phase 3 trial using Glypromate product to modulate the cognitive impairment in patients undergoing cardiac surgery with bypass was failed. However, in the last decade, variegated neuropeptides derived from IGF-I were found to exhibit adequate protection and more favorable pharmacokinetic profile compared to IGF-I [11,12].

Figure 1. Design and development of GPEs peptidomimetics starting from native GPE.

Nonetheless, the therapeutic potentials of GPEs remain limited, owing to the role of peptidases in degradation process. Again, metabolic stability results indicated that GPE has a very short plasma half-life, and this consequence restricts its central nervous system (CNS) delivery. Therefore, development of novel neuropeptides to overcome the limitations of their endogenous counterparts would provide a fruitful drug discovery approaches for treatment of AD. To eliminate these stability issues, different strategies were applied for modification of GPE molecule, since its structural simplicity open a new route for the synthesis of sterically hindered peptides and/or non-peptide derivatives with increased bioavailability and improved metabolic stability [13].

Previously, an intimate elaboration was made for the replacement and/or modification of GPE amino acid sequence to (I) improve its proteases resistance and (II) manage and retaining its neuroprotective feature [12]. Therefore, the introduction of peptide bond surrogates has been recommended as an effective strategy to prolong the lifetime of peptides, improve the biological activity or selectivity, design enzyme inhibitors, and induce conformational features. Thus, we obtained three novel GPE peptidomimetics (GPE1, GPE2, and GPE3), with peptide bonds reduced to an aminomethylene group at the Gly-Pro (GPE3) or Pro- Glu (GPE1), or both the junctions (GPE2) to improve the stability against proteolytic attacks still exhibiting their biological activity (Figure 1). Preliminary data showed that the introduction of the aminomethylene unit into the GPE sequence would provide stable GPE 1-3 pseudotripeptides (Figure 1). As we expected, the removal of the amide bond with an isosteric group would increase the half-life of the three pseudotripeptides compared to that of GPE. Notably, plasma stability features showed a half-life ($t_{1/2}$) > 4.5 h that would permit them to reach unaltered the site of action (neuroinflammed areas) in the CNS [12].

Herein, we aimed to evaluate the multi-target profile exerted by the novel GPE peptidomimetics and propose them as potential anti-Alzheimer drug candidates in AD therapy. With this design, the anti-Alzheimer evaluations were materialized with a wide range of basic techniques in the cellular AD model. These techniques, include (I) measurements of mitochondrial viability (MTT) and lactate dehydrogenase (LDH) release (II) determination of AChE, α-secretase and β-secretase activities, (III) establishment of total antioxidant capacity (TAC) and total oxidative status (TOS) levels, (IV) flow cytometric and microscopic
detection of apoptotic and necrotic neuronal death, and (V) definition of molecular genetic responses via PCR arrays.

2. Materials and Methods

Synthesis of GPE1-3 was conducted by Marinelli et al. [12]. All reagents for the synthesis of compounds were procured from Sigma-Aldrich (St. Louis, MO, USA).

2.1. The Cellular Model of AD

The SH-SY5Y cell line (ATCC CRL-2266) was obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Cell cultures were grown in DMEM: F12 (1:1) (Gibco, Grand Island, NY, USA) with 10% fetal bovine serum (FBS) (Sigma-Aldrich, St Louis, MO, USA) and 1% penicillin/streptomycin (Sigma-Aldrich) at 37 °C and 5% CO2. After the cultures reached 80% confluence, the cells were detached from the flask’s surface using trypsin/EDTA (Sigma-Aldrich) solution and then seeded to 48 well plates. For the differentiation procedure, 10 µM RA (Sigma-Aldrich) was added to the media and incubated for a week. Afterward, the media were supplemented with 25 nM BDNF (Promega, Fitchburg, WI, USA) for another 5 days to complete cellular differentiation. Differentiated cells were determined under the inverted microscope (Olympus CKX41, Düsseldorf, Germany) and flow cytometric cell cycle analysis. The cells were used within 7 days [14–16]. Briefly, differentiated and undifferentiated cell cultures were stained with 5 µL propidium iodide (PI, 50 µg/mL), and then were incubated at room temperature in the dark for 5 min. Next, a flow cytometer (Partec, Muenster, Germany) was used to analyze the cellular DNA content frequency histograms for cell distributions in three major cycle phases (G1 vs. S vs. G2/M).

2.2. Treatments

Different concentrations of GPE, GPE1, GPE2, GPE3, memantine hydrochloride (MEM) (0.1, 1, 10, 25, 50, and 100 µM), and Aβ1-42 (20 µM) (Sigma-Aldrich) were applied to differentiated cell culture for 24 h (n = 5). For negative control, non-treated differentiated cell culture was investigated. The tripeptide glycine-proline-glutamate abbreviated as GPE was used to compare novel peptidomimetics’ biological effects (GPE1-3). A 1% Triton-X as a nonionic detergent, ascorbic acid (10 µM) as an effective antioxidant, and H2O2 (25 µM) as an oxidizing agent (Sigma-Aldrich) were used as positive controls for cell viability, TAC, and TOS analysis, respectively. AChE activity was compared to Galantamine hydrobromide (GAL) as an anticholinesterase drug (Sigma-Aldrich). Likewise, gallic acid (GA) (Sigma-Aldrich) was used as a positive control for α-secretase and β-secretase activity assays.

2.3. MTT Assay

Cell proliferation was analyzed using MTT commercially available assay kits (Cayman Chemical Company, Ann Arbor, MI, USA). After the medium aspirating process of 170 µL MTT solution was added to each well. Plates were incubated for 3 h at 37 °C, and then were centrifuged at 1200 rpm for 3 min. The formazan crystals were dissolved in 200 µL dimethyl sulfoxide (DMSO) (Sigma-Aldrich). Absorbance at 570 nm was measured using a plate reader (BioTek, Winooski, VT, USA). Cell viability rates (n = 5) were calculated as percentage relative to the untreated control value [17,18].

2.4. LDH Assay

LDH cytotoxicity assay (Cayman Chemical Company) was performed according to the manufacturer’s recommendations. The cells were incubated in 48-well plates, and different concentrations of drugs were exposed for 24 h (n = 5). Subsequently, 100 µL supernatant and 100 µL of the reaction mixture were placed on a fresh 48-well plate and incubated for 30 min. Next, a microplate reader measured the absorbance of the samples at 490 nm [19].
2.5. Determination of AChE Activity
The colorimetric kits from Abcam (Cambridge, MA, USA) were used to analyze AChE activity for the cellular AD model (n = 5) according to the manufacturer’s instructions [20].

2.6. Determination of β-Secretase and α-Secretase Activities
The activities of β-secretase and α-secretase enzymes in e differentiated SH-SY5Y cultures (n = 5) were measured by the commercially available fluorometric activity detection kits (Sigma-Aldrich) according to the provider’s recommended protocols [16].

2.7. TAC and TOS Analysis
In the TAC assay, antioxidants in samples obtained from the cellular AD model reduce dark bluish-green colored 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) to a colorless reduced form of ABTS. The recorded change in absorbances at 660 nm is correlated with the sample’s total antioxidant capacity. TAC assay was calibrated using a vitamin E analogue, named as Trolox equivalent. In TOS assay, remaining oxidants in samples quickly oxidize the ferrous ion–chelator complex to ferric ion. The reaction medium also contains a wealth of enhancer molecules to prolong the oxidation reaction. The ferric ion produces a colored complex with chromogen. The spectrophotometrically determined color intensity is directly related to the total oxidant molecules available in the sample. The TOS assay was calibrated using H$_2$O$_2$, and the results are presented as µM H$_2$O$_2$ equivalent per liter. The automated TAC and TOS assays were performed using commercially available kits (n = 5) (Rel Assay, Gaziantep, Turkey) [21,22].

2.8. Apoptosis Detection by Hoechst 33258 Staining
Hoechst 33258 staining was used for morphological assessment of apoptotic cells. The untreated and treated cells were fixed with 4% paraformaldehyde in phosphate-buffered saline at 4 °C for 20 min. The cells were washed twice with PBS and then stained with 1 mM 33258 fluorescent dye (Sigma-Aldrich). Cells (n = 5) were observed and photographed under fluorescence microscopy (Leica DM IL LED, Wetzlar, Germany) [23].

2.9. Apoptosis-Necrosis Assay
The frequencies of viable, apoptotic, and necrotic cells were determined using the Annexin V-FITC apoptosis detection kit I (BD Pharmingen, Waltham, MA, USA). For each sample (n = 5), 5 × 10^4 cells were mixed with 500 µL of 1 × binding buffer. A 5 µL of Annexin V-FITC and 5 µL propidium iodide (PI, 50 µg/mL) were added to the samples and incubated at room temperature for 5 min in the dark. Finally, CyFlow Cube 6 flow cytometer (Partec) system was used to determine apoptotic and necrotic cell death ratios [24].

2.10. Molecular Genetic Analysis
The complete molecular genetic analyses were performed in three stages, as described below.

2.10.1. Total RNA Isolation
A 5 × 10^6 undifferentiated SHSY-5Y cells were seeded in a 6-well plate and differentiated into neuron-like cell culture via all-trans retinoic acid applications. Then, the cultures were treated with the selected concentration of the effective compounds for 24 h in 5% CO$_2$. Total RNA was isolated using the PureLink RNA Mini Kit (Invitrogen, Grand Island, NY, USA) as described by the manufacturer. Briefly, the growth medium was removed from the cells, and 0.6 mL lysis buffer prepared with 2-mercaptoethanol was added to the sample. Then the lysate was transferred to 1.5 mL RNase-free tube and passed through an 18-21-gauge needle for 5–10 times. Following homogenization, the cell homogenate was washed with 70% ethanol and mixed thoroughly to disperse any visible residue. The sample was transferred to the spin cartridge (with the collection tube), centrifuged at
12,000× g for 15 s at room temperature. RNA was eluted from the membrane by adding 100 µL RNase–Free Water to the center of the Spin Cartridge. Finally, RNA yield and quality were determined using a plate reader (Multiskan, Thermo Labsystems, Vantaa, Finland) at wavelengths of 260 nm and 280 nm.

2.10.2. cDNA Synthesis

Isolated total RNA was reverse transcribed into cDNA using High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) according to the provider’s manual. A 2× T master mix was prepared using kit components including 10× RT Buffer, 25× dNTP Mix (100 mM), 10× RT Random Primers, Reverse Transcriptase, and nuclease-free H2O. RNA samples were mixed with 2× RT master mix and loaded to thermal cycler (Sensquest, Goettingen, Germany). The reaction was carried out at 25 °C for 10 min, at 37 °C for 120 min, then at 85 °C for 5 min. The cDNA was used directly for RT-PCR amplification or stored at −20 °C.

2.10.3. PCR Array

The total cDNA was used in expression analysis via RT2 Profiler PCR Array Human Molecular Toxicology Pathway Finder (Qiagen, Valencia, CA, USA). To carry out the PCR array, 1150 µL SYBR Green PCR Master Mix (Applied Biosystems), 102 µL cDNA synthesis reaction, and 1048 µL RNase-free water was mixed. A 20 µL PCR components mix was added to each well of the RT2 Profiler PCR Array. Then, the RT2 Profiler PCR Array was sealed with Rotor-Disc Heat-Sealing Film using the Rotor-Disc Heat Sealer and loaded to real-time cycler (Qiagen Rotor-Gene Q). Triple repeated reactions were started with an initial denaturation step of 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C and 30 s at 60 °C. Melting curve analysis was utilized to validate the presence of a single PCR product. The threshold value was set above background signal, but within the lower one third to one half of the linear phase of the amplification plot. CT Cut-off value was selected as 35 cycle (program default) for the analyses. Data analysis was followed out with the ΔΔCt method with normalization of the raw data to 5 different housekeeping genes, including beta-actin (ACTB), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), heat shock protein 90 kDa alpha (HSP90AB1), phosphoglycerate kinase 1 (PGK1), and ribosomal protein lateral stalk subunit P0 (RPLP0). In the real time analysis, relative expressions were calculated using Livak (2−ΔΔCt) method that normalize the CT values according to the reference genes. CT values were used for analyzing fold changes of gene expression using PCR Array Data Analysis Software (The GeneGlobe Data Analysis Center, Qiagen) [25]. In the context of molecular genetic studies, 64 essential genes in 10 different biological pathways were evaluated.

2.11. Statistical Analyses

The data are presented as mean ± SD from at least five independent experiments. For statistical analyses, a one-way analysis of variance (ANOVA) and Tukey test was used using GraphPad Prism version 7. A p-value of less than 0.05 was considered as statistically significant.

3. Results and Discussion

3.1. Aβ1-42 Treatments Induced Cell Death in Differentiated SH-SY5Y Cells

SH-SY5Y human neuroblastoma cells’ differentiation process to neuronal-like cells included using a combination of RA and BDNF. According to the cell cycle analysis, total cells in the both S and G1 phases were significantly (p < 0.05) increased in differentiated SH-SY5Y cells compared to undifferentiated cell cultures (Figure 2). To choose the most appropriate Aβ1-42 concentration for anti-AD assessments, a wide range of Aβ concentrations involving 1.25, 2.5, 5, 10, 20, 40, 80, 160, and 320 µM were applied into the cellular model for 24 h (n = 6). After exposing the SH-SY5Y cells with differentiation to Aβ1-42, cell viability rates were determined by MTT assay. The MTT assay results showed that Aβ induced
toxicity in a concentration-dependent manner (Table 1). The highest concentration (320 μM) caused the sterility of the cultures. The lowest concentration (1.25 μM) induced cell death at a rate of 18.74% compared to control. The half-maximal inhibitory concentration (IC₅₀) is generally used to measure drug potency in pharmacological research. A rate of 51.84% was calculated after exposure to 20 μM Aβ₁₋₄₂; thus the protocol using the 24 h treatment of 20 μM Aβ₁₋₄₂ was selected for further experimental works [18].

Figure 2. (A) Undifferentiated SHSY5Y cells, (B) differentiated SHSY5Y cells using a combination of RA+BDNF (40 × magnifications) and (C) cell cycle analysis via flow cytometry. Statistical analysis was performed using a one-way ANOVA followed by Tukey’s post-hoc test. Symbol (*) used for statistically significant (p < 0.05) change in each cell cycle phase.

Table 1. Cytotoxicity of Aβ₁₋₄₂ on differentiated SH-SY5Y cells.

| Group                | Cell Viability (as %) |
|----------------------|-----------------------|
| Control              | 100                   |
| Aβ₁₋₄₂ concentrations (as μM) |  
| 1.25                 | 81.26 ± 5.06          |
| 2.5                  | 73.42 ± 5.24          |
| 5                    | 66.93 ± 6.55          |
| 10                   | 61.41 ± 4.87          |
| 20                   | 51.84 ± 5.21          |
| 40                   | 43.65 ± 4.38          |
| 80                   | 32.11 ± 4.22          |
| 160                  | 11.22 ± 2.78          |

3.2. Neuroprotective Potentials of Novel GPEs on Aβ₁₋₄₂-Induced Cytotoxicity in In Vitro Cellular AD Model

The MTT and LDH cytotoxicity assays were used to investigate the effects of GPE, novel GPEs (as GPE1, GPE2 and GPE3), and MEM against Aβ₁₋₄₂ induced cytotoxicity. The cytotoxicity analyses were used to monitor membrane damage (LDH leakage) and mitochondrial function (MTT reduction) to calculate relative cell viability compared to negative control. The cultures without GPEs or MEM were assigned as negative control, and 1% Triton-X was used to stimulate positive control with Aβ₁₋₄₂ treatment.

We determined statistically significant (p < 0.05) cell viability reductions at 20 μM of Aβ₁₋₄₂ treatment for 24 h. We obtained cell viability ratios of 52.73% and 44.28, in MTT and LDH, after Aβ-exposure. When different GPEs and MEM concentrations (0.1, 1, 10, 25, 50, and 100 μM) were used alone into the cell cultures, all concentrations (except 100 μM for MEM) did not alter the cell viability rates in comparison to untreated cells (p > 0.05). The...
observed cell viability rates after treatments with 100 µM MEM were 91.34% and 88.75% in MTT and LDH assays, respectively (Supplementary Figures S1 and S2). Based on this result, we revealed that the highest concentration of MEM would cause cytotoxicity on neuronal-like cells. In line with our finding, a previous report proved that MEM would influence intracellular pathways involved in cellular survival and/or apoptotic processes. Likewise, the cytotoxic action of 100 µM MEM was also recorded in cultured human peripheral blood and mouse N2a neuroblastoma cells [26].

MTT assay pointed out the significant inhibition of SH-SY5Y cell viability by \( A\beta_{1-42} \) application (\( p < 0.05 \)). Treatments with GPEs and MEM increased the number of viable cells significantly more than cells treated with \( A\beta_{1-42} \) only. The neuroprotective action was associated with agent type and concentration. The addition of GPE3 at a various concentration rates tend to decrease cell damage induced by \( A\beta_{1-42} \) than others (Figure 3). Similarly, results by LDH release assay were in accordance with those of MTT assay (Figure 4). A100 µM GPE3 showed the most protective effect. Moreover, cell viability analyses indicate a dose-dependent relationship between formulations and neuroprotective capabilities.

The MTT assay centers on the mitochondrial metabolic capacity of alive cells and the state of intracellular redox [27]. SH-SY5Y cells were treated with \( A\beta_{1-42} \) for 24 h, and the \( A\beta \)-induced neurotoxicity was monitored via MTT assay. \( A\beta \) application led to a remarkable decrease in cell viability (20 µM; about 48%). Co-treatment with different concentrations of GPEs or MEM modulate \( A\beta \)-induced cytotoxicity. MTT testing revealed that differentiated SH-SY5Y cell cytotoxicity was minimized by co-treatments with GPEs or MEM concentrations. All tested formulations inhibited cell death induced by \( A\beta \)-exposure, resulting in a respective increase in the cell viability by 13.1, 12.0, 16.4, 31.8, and 16.6% for GPE, GPE1, GPE2, GPE3, and MEM at a concentration rate of 100 µM, in MTT assay.
For evaluating the probability of Aβ-induced membrane damage, LDH assay was used to explore the protective effect of GPEs and MEM, measuring the activity of LDH released into the medium from necrotic and/or apoptotic SH-SY5Y cells. LDH assay fixed up an overlook for the percentage of surviving neuronal-like cells. With Aβ1-42 treatment for 24 h, the released LDH enzyme by SH-SY5Y cells increased to a rate of 55.72% compared to negative control group. Present results denote that GPEs and MEM would protect the SH-SY5Y cell membrane against Aβ-induced neurotoxicity. Indeed, all GPEs and MEM inhibited cell death induced by Aβ-exposure, resulting in significant increases ($p < 0.05$) in the cell viability by 20.5, 19.5, 20.3, 41.7, and 24.5% for GPE, GPE1, GPE2, GPE3 and MEM treatments at a concentration of 100 µM, respectively, in LDH assay.

3.3. The In Vitro Effects of Novel GPEs on AChE Activity

Recent transcriptional profiling data indicate that either undifferentiated or differentiated SH-SY5Y cells contain AChR mRNA and express nearly half of acetylcholine (ACh) receptor subunits [28]. Moreover, Aβ25-35 or Aβ1-42 led to significant increases in AChE expression in neuron-like human neuroblastoma cells [29]. Therefore, to find out the effects of GPEs on AChE activity in comparison to anticholinesterase drug, GAL, the differentiated SH-SY5Y cells were treated with GPEs and GAL or media alone for 24 h and then assessed for AChE activity (Figure 5). We found that 20 µM Aβ1-42 approximately increased the baseline AChE activity by two-fold. However, treatment with GAL substantially regulated Aβ-induced AChE activity. However, treatments with GPEs provided such a slight modulation. In fact, GPE, GPE1, GPE2, and GPE3 (at only 100 µM) could reduce Aβ-stimulated AChE activity at a rate of 19.35%, 16.93%, 18.54%, and 20.96% respectively (Figure 4). Present results clearly showed that all GPEs worked, but only at very high concentrations than GAL. At this point, several in vivo findings revealed that GPE has the potency to induce AChE released from cortical and striatal neuron cells, however the molecular justification of AChE released by GPE is still unclear [30]. The chemically modified GPE compound has been shown to have an opposite effect on AChE activity, due to modifications in its active groups. In this regard, the present results firstly indicate that GPEs would regulate the AChE activity via exhibiting a mild level of AChE inhibiting feature.

![Image](image_url)

**Figure 5.** The effects of novel GPEs applications on Aβ1-42-induced AChE activity ($n = 5$). Statistical analysis was performed using a one-way ANOVA followed by Tukey’s post-hoc test. Symbol (*) represents a statistically significant ($p < 0.05$) decrease in AChE activity compared to beta-amyloid.
3.4. The In Vitro Effects of Novel GPEs on β-Secretase and α-Secretase Activities

Table 2 presents the results of measurement of α-secretase activity in differentiated SH-SY5Y cells treated with GPEs, Aβ1-42, or a combination of them. The GA application (at 50 μM, as positive control) concurrently led to a statistically (p < 0.05) significant increase in α-secretase activity, while reduced the activity of β-secretase in differentiated SH-SY5Y cell cultures. Similar to this finding, dual α- and β-secretase modulating effects by GA were also reported in clinical mouse model of AD [31]. Our analysis also clearly indicates that Aβ1-42 treatment for 24 h would lead to a significant decrease (p < 0.05) of α-secretase activity compared to untreated cultures. Collaterally to this finding, the levels of α-secretase were found to be significantly lower in AD patients than in controls [32]. A previous report stated that when differentiated SH-SY5Y cells exposed to Aβ1-42, the activity of α-secretase was prominently decreased [33]. Therefore, α-secretase activation was generally considered to be of therapeutic value [34]. A 50 and 100 μM of GPE and GPE3 supported the increases of α-secretase activity against Aβ1-42-induced inactivation, however, the other GPEs were found to be ineffective in α-secretase activity. This is the first proof, which declares that certain GPE analogs would have a positive impact on α-secretase activity.

Table 2. The effects of GPEs on α-secretase and β-secretase activities (as fluorescence intensity/100 μg protein). Statistical analysis was performed using a one-way ANOVA followed by Tukey’s post-hoc test. Means (n = 5) with the same letter in the same column are not significantly different at p = 0.05.

| Group              | α-Secretase Activity | β-Secretase Activity |
|--------------------|----------------------|----------------------|
| Control (+)        | 18.8 ± 3.6 c          | 2854.5 ± 308.6 b     |
| Control (+)        | 27.6 ± 4.7 d          | 1635.6 ± 211.8 a     |
| 20 μM Aβ1-42       | 6.2 ± 1.3 a           | 6884.8 ± 545.0 c     |
| Aβ +0.1 μM GPE     | 6.1 ± 1.1 a           | 6775.4 ± 478.2 c     |
| Aβ +1 μM GPE       | 6.4 ± 1.0 a           | 6841.6 ± 396.5 c     |
| Aβ +10 μM GPE      | 6.8 ± 1.2 a           | 6692.0 ± 383.4 c     |
| Aβ +25 μM GPE      | 7.4 ± 1.4 a           | 6735.5 ± 411.7 c     |
| Aβ +50 μM GPE      | 10.6 ± 1.4 b          | 6689.2 ± 549.4 c     |
| Aβ +100 μM GPE     | 12.5 ± 1.7 b          | 6714.4 ± 661.0 c     |
| Aβ +0.1 μM GPE1    | 6.0 ± 0.8 a           | 7028.7 ± 486.6 c     |
| Aβ +1 μM GPE1      | 6.3 ± 1.1 a           | 6894.4 ± 463.1 c     |
| Aβ +10 μM GPE1     | 6.7 ± 1.0 a           | 6838.5 ± 474.1 c     |
| Aβ +25 μM GPE1     | 6.9 ± 1.4 a           | 6845.4 ± 504.5 c     |
| Aβ +50 μM GPE1     | 7.1 ± 1.2 a           | 6771.2 ± 522.2 c     |
| Aβ +100 μM GPE1    | 7.4 ± 1.4 a           | 6768.4 ± 478.2 c     |
| Aβ +0.1 μM GPE2    | 6.1 ± 1.0 a           | 7014.1 ± 506.0 c     |
| Aβ +1 μM GPE2      | 6.4 ± 1.1 a           | 7012.0 ± 543.6 c     |
| Aβ +10 μM GPE2     | 6.4 ± 1.3 a           | 6861.4 ± 431.5 c     |
| Aβ +25 μM GPE2     | 6.7 ± 1.4 a           | 6844.5 ± 447.7 c     |
| Aβ +50 μM GPE2     | 7.0 ± 1.5 a           | 6864.2 ± 391.2 c     |
| Aβ +100 μM GPE2    | 7.2 ± 1.3 a           | 6785.0 ± 488.0 c     |
| Aβ +0.1 μM GPE3    | 6.1 ± 1.7 a           | 6930.3 ± 512.6 c     |
| Aβ +1 μM GPE3      | 6.2 ± 1.3 a           | 6981.4 ± 455.2 c     |
| Aβ +10 μM GPE3     | 6.9 ± 1.5 a           | 6873.5 ± 476.6 c     |
| Aβ +25 μM GPE3     | 7.3 ± 1.3 a           | 6865.6 ± 442.0 c     |
| Aβ +50 μM GPE3     | 10.5 ± 1.6 b          | 6756.2 ± 465.6 c     |
| Aβ +100 μM GPE3    | 12.8 ± 1.8 b          | 6776.0 ± 511.8 c     |

On the other hand, targeting β-secretase (BACE1) is also considered a very rational approach since this enzyme’s level is increased in the brain of patients with AD [35]. Similarly, the addition of Aβ1-42 into the SH-SY5Y growth medium tend to increase β-secretase activity [36]. Following these previous reports, the present results indicate that Aβ1-42 caused about 2.4-fold increases in β-secretase activity. At variance, the applications with different concentrations of GPEs did not alter β-secretase activity in cultured differentiated SH-SY5Y cells. However, the co-applications with novel GPEs could not reduce the increased level
of β-secretase by Aβ1-42 (Table 2). Thus, it is concluded that GPEs are not associated with β-secretase activity and amyloidogenic APP processing in vitro.

3.5. Effects of Applications with Novel GPEs on TAC and TOS Levels in the Cellular Model of AD

The effects of treatments with novel GPEs on TAC and TOS levels in the AD cellular model were evaluated (Tables 3 and 4). The results revealed that all GPEs supported TAC levels. Indeed, the GPEs at 100 μM led to significant increases in TAC levels compared to control (-) cultures. GPE, GPE1, GPE2, GPE3, and ascorbic acid (10 μM, as positive control) increased TAC levels in about 2.37, 2.16, 1.97, 2.51- and 2.75-fold changes. On the contrary, only H2O2 (25 μM, as positive control) treatment caused significant increases (approximately 2.9-fold) of TOS levels. However, treatments with all GPEs did not alter the measured TOS levels compared to untreated controls ($p > 0.05$). The decreasing order of supporting antioxidant capacity by compounds were as GPE3 > GPE > GPE1 > GPE2. The obtained results also revealed that Aβ1-42 exposure caused significant ($P < 0.05$) decreases of TAC and increases of TOS levels in vitro. In the same trend, 20 μM Aβ1-42 treatment reduced TAC level by about 0.6-fold and enhanced TOS level about 2.3-fold. On the contrary, these negative alterations were modulated by GPE and its novel analogs co-treatment with Aβ1-42. GPE3 was more effective than other tested GPEs in alleviating oxidative stress by Aβ1-42-exposure (Tables 3 and 4).

Table 3. The effects of GPEs on TAC and TOS levels in cultured differentiated SH-SY5Y cells. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc test. Means (n = 5) with the same letter in the same column are not significantly different at $p = 0.05$.

| Group   | TAC Level (μmol Trolox Equiv./L) | TOS Level (μmol H2O2 Equiv./L) |
|---------|---------------------------------|---------------------------------|
| Control (-) | 5.08 ± 0.62 $^a$ | 1.66 ± 0.22 $^a$ |
| Control (+) | 13.96 ± 1.14 $^c$ | 5.45 ± 0.42 $^b$ |
| GPE      |                                |                                |
| 0.1 μM   | 5.22 ± 0.41 $^a$ | 1.77 ± 0.27 $^a$ |
| 1 μM     | 5.49 ± 0.57 $^a$ | 1.81 ± 0.21 $^a$ |
| 10 μM    | 6.38 ± 0.48 $^b$ | 1.88 ± 0.14 $^a$ |
| 25 μM    | 8.69 ± 0.63 $^bc$ | 1.83 ± 0.20 $^a$ |
| 50 μM    | 10.91 ± 0.57 $^c$ | 1.87 ± 0.22 $^a$ |
| 100 μM   | 12.08 ± 0.96 $^c$ | 1.90 ± 0.18 $^a$ |
| GPE1     |                                |                                |
| 0.1 μM   | 5.06 ± 0.35 $^a$ | 1.84 ± 0.20 $^a$ |
| 1 μM     | 5.38 ± 0.51 $^a$ | 1.73 ± 0.16 $^a$ |
| 10 μM    | 6.79 ± 0.39 $^b$ | 1.82 ± 0.18 $^a$ |
| 25 μM    | 8.25 ± 0.70 $^{bc}$ | 1.68 ± 0.20 $^a$ |
| 50 μM    | 9.78 ± 0.61 $^c$ | 1.83 ± 0.22 $^a$ |
| 100 μM   | 11.02 ± 0.94 $^c$ | 1.95 ± 0.22 $^a$ |
| GPE2     |                                |                                |
| 0.1 μM   | 5.08 ± 0.40 $^a$ | 1.73 ± 0.26 $^a$ |
| 1 μM     | 5.21 ± 0.61 $^a$ | 1.85 ± 0.21 $^a$ |
| 10 μM    | 5.93 ± 0.71 $^a$ | 1.91 ± 0.26 $^a$ |
| 25 μM    | 7.44 ± 0.58 $^b$ | 1.87 ± 0.18 $^a$ |
| 50 μM    | 8.68 ± 0.56 $^{bc}$ | 1.93 ± 0.20 $^a$ |
| 100 μM   | 10.04 ± 0.83 $^c$ | 1.98 ± 0.28 $^a$ |
| GPE3     |                                |                                |
| 0.1 μM   | 5.25 ± 0.30 $^a$ | 1.66 ± 0.22 $^a$ |
| 1 μM     | 5.86 ± 0.43 $^a$ | 1.64 ± 0.18 $^a$ |
| 10 μM    | 7.73 ± 0.54 $^b$ | 1.74 ± 0.16 $^a$ |
| 25 μM    | 9.18 ± 0.66 $^c$ | 1.88 ± 0.25 $^a$ |
| 50 μM    | 10.94 ± 0.64 $^c$ | 1.81 ± 0.21 $^a$ |
| 100 μM   | 12.74 ± 0.87 $^d$ | 1.89 ± 0.17 $^a$ |

Following these present findings, it was reported that Aβ1-42 increased the vulnerability of SH-SY5Y cells to oxidative stress [37]. It was evidenced that Aβ1-42 initiated lipid peroxidation via inserting as oligomers into the bilayer and serving as a ROS source [38]. In addition to above mentioned in vitro studies, Aβ1-42 treatments led to increase of superoxide dismutase (SOD) and catalase (CAT) enzyme activities, decrease of glutathione peroxidase (GSH-Px) activity and the total content of the reduced glutathione (GSH) and enhancement of malondialdehyde (MDA) and protein carbonyl levels in the hippocampus.
regions of rats [39]. Likewise, application with Aβ1-42 generated ROS, 3-nitrotyrosine (3-NT), 4-hydroxy-nonenal (4-HNE), and 8-hydroxy-2’-deoxyguanosine (8-OH-DG) products in the mouse model of AD [40,41].

Table 4. The effects of GPEs on TAC and TOS levels in a cellular experimental model of AD (n = 5). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post-hoc test. Means with the same letter in the same column are not significantly different at p = 0.05.

| Groups          | TAC Level (mmol Trolox equiv./L) | TOS Level (μmol H₂O₂ equiv./L) |
|-----------------|---------------------------------|-------------------------------|
| Control (-)     | 5.08 ± 0.62 b                   | 1.86 ± 0.24 a                 |
| Control (+)     | 13.96 ± 1.14 f                  | 5.45 ± 0.42 d                 |
| 20 μM Aβ1-42    | 3.22 ± 0.58 a                   | 4.37 ± 0.40 c                 |
| Aβ +0.1 μM GPE  | 3.89 ± 0.46 a                   | 4.09 ± 0.36 bc                |
| Aβ +1 μM GPE    | 4.95 ± 0.61 b                   | 3.85 ± 0.34 b                 |
| Aβ +10 μM GPE   | 6.24 ± 0.54 bc                  | 3.27 ± 0.40 b                 |
| Aβ +25 μM GPE   | 7.12 ± 0.63 c                   | 2.89 ± 0.33 b                 |
| Aβ +50 μM GPE   | 9.65 ± 0.72 d                   | 2.60 ± 0.20 b                 |
| Aβ +100 μM GPE  | 10.04 ± 0.79 d                  | 2.34 ± 0.28 b                 |
| Aβ +0.1 μM GPE1 | 3.41 ± 0.52 a                   | 4.13 ± 0.26 c                 |
| Aβ +1 μM GPE1   | 4.35 ± 0.54 ab                  | 3.96 ± 0.32 bc                |
| Aβ +10 μM GPE1  | 5.12 ± 0.47 b                   | 3.63 ± 0.34 b                 |
| Aβ +25 μM GPE1  | 5.34 ± 0.45 b                   | 3.17 ± 0.35 b                 |
| Aβ +50 μM GPE1  | 5.71 ± 0.50 b                   | 2.87 ± 0.21 b                 |
| Aβ +100 μM GPE1 | 6.33 ± 0.55 bc                  | 2.66 ± 0.23 b                 |
| Aβ +0.1 μM GPE2 | 3.88 ± 0.42 a                   | 4.02 ± 0.30 bc                |
| Aβ +1 μM GPE2   | 4.22 ± 0.51 a                   | 3.84 ± 0.42 b                 |
| Aβ +10 μM GPE2  | 4.41 ± 0.39 a                   | 3.56 ± 0.33 b                 |
| Aβ +25 μM GPE2  | 4.49 ± 0.53 a                   | 3.29 ± 0.25 b                 |
| Aβ +50 μM GPE2  | 4.83 ± 0.51 b                   | 3.08 ± 0.26 b                 |
| Aβ +100 μM GPE2 | 6.38 ± 0.55 bc                  | 2.93 ± 0.30 b                 |
| Aβ +0.1 μM GPE3 | 4.15 ± 0.35 a                   | 4.06 ± 0.28 bc                |
| Aβ +1 μM GPE3   | 4.78 ± 0.47 b                   | 3.66 ± 0.36 b                 |
| Aβ +10 μM GPE3  | 5.34 ± 0.45 b                   | 3.15 ± 0.27 b                 |
| Aβ +25 μM GPE3  | 7.66 ± 0.81 c                   | 2.71 ± 0.32 ab                |
| Aβ +50 μM GPE3  | 9.86 ± 0.73 d                   | 2.55 ± 0.18 ab                |
| Aβ +100 μM GPE3 | 10.93 ± 0.88 e                  | 2.17 ± 0.26 a                 |

In the light of the present results, GPEs are shown to execute different degrees of antioxidative potential without leading pro-oxidative alterations. Moreover, co-treatment with GPEs decreased TOS and increased TAC levels compared with the Aβ1-42-treated group. These results propose that GPEs play a protective role against oxidative stress, which indicates that the antioxidant effects of GPEs are involved in the neuroprotection mechanism. Concordantly, this study’s results clearly revealed that novel GPEs propounded high antioxidative potency for the first time. It is well known that AD is a progressive neurodegenerative disease in aging brains and asserts a long and relatively asymptomatic prodromal phase. There is still no exact and efficient treatment option for AD [42]. Therapeutic approaches targeting the triggers (oxidative stress, neuronal apoptosis, etc.) of AD are being considered to produce the most significant advantage if applied during the prodromal phase or earlier [43]. In this regard, GPEs might slow the progression or delay the onset of AD.

3.6. Effects of Novels GPEs on Apoptosis and Necrosis in the Cellular Model of AD

Staining with Hoechst 33258 and visual examination revealed that a co-treatment with GPEs inhibited apoptosis by Aβ1-42 at different levels (Figure 6A–D). The visual observations using apoptosis-necrosis assay indicated that Aβ1-42 toxicity occurred via a necrotic or late apoptotic rather than the early apoptotic condition because of their smear-looking nucleus as indicated in several reports [44]. This assay demonstrated that GPE3 provided more protection potential from Aβ1-42-induced necrosis and late apoptosis.
in a dose-dependent manner than other GPEs and MEM. These results were correlated and quantified in the flow cytometry analysis (Figure 7). Since MEM could exhibit slight cytotoxicity at 100 µM, all comparisons were made only at 50 µM concentrations. And the decreasing order of effectiveness of GPEs and MEM against Aβ1-42-induced apoptosis were assessed as GPE3 > MEM > GPE > GPE1 > GPE2 [45].

Figure 6. Effects of GPE and GPE3 on apoptosis and necrosis in cellular model of AD (Hoechst 33258) (n = 5), (A) Untreated group, (B) Aβ1-42 (20 µM), (C) GPE3 (50 µM) + Aβ1-42, (D) GPE (50 µM) + Aβ1-42. Red arrows indicate necrotic cells with damaged chromosomal structures.

Figure 7. Flow cytometric analysis of Annexin V-FITC (FL1)/PI (FL2) double-labeled cells in a cellular model of AD (n = 5), (A) negative control, (B) Aβ1-42, (C) MEM (50 µM) + Aβ1-42, (D) GPE (50 µM) + Aβ1-42. All experimental groups were shown in one graph. Statistical analysis was performed using a one-way ANOVA followed by Tukey’s post-hoc test. Symbol (*) represents a statistically significant (p < 0.05) increase in cell viability compared to beta-amyloid application.
Due to the determined higher potential of neuroprotection (MTT, LDH assays, and Hoechst 33258 staining), AChE inhibition potential, and antioxidative power against Aβ1-42-induced neurotoxicity in cellular AD model, further flow cytometric analysis was continued with GPE3. The effectiveness of GPE3 against Aβ1-42-induced apoptosis and necrosis was determined in comparison to MEM using flow cytometry. Flow cytometric analysis of apoptosis and necrosis showed that Aβ1-42 application caused a significant ($p < 0.05$) cell death rate (34.39%) via apoptosis and a slight death rate (3.68%) via necrosis. On the contrary, GPE3 and MEM decreased the apoptotic cell percentage compared to Aβ1-42 application by 22.8 and 31.03, respectively. In brief, GPE3 was considered more able to protect the human neuron-like cells from Aβ1-42-induced necrosis and apoptosis than MEM (Figure 7A–D).

3.7. Molecular Genetic Responses to GPE3 in Cellular AD Model

From the above-detailed results, it is reasonably concluded that GPE3 is the best GPE analog showing neuroprotective action against Aβ1-42 induced neurotoxicity in vitro. To determine the exact molecular mechanisms underlying this neuroprotection by GPE3, RT2 Profiler PCR Arrays were applied. For this aim, different total RNA samples from each treatment were characterized via the human inflammatory cytokines and receptors, and the percentage of detectable genes was calculated for each amount. In this case, the PCR array could detect individual genes, despite the expression of related gene-family members in the same RNA sample. The observed gene expression changes after treatment with Aβ1-42 (20 µM) and GPE3 (50 µM) plus Aβ1-42 (20 µM) in comparison to untreated cells are presented in Supporting information (Table 5). In the content of molecular genetic studies, 64 essential genes in 10 different biological pathways were evaluated and discussed.

**Table 5.** The gene expression alterations (as fold change).

| Gene      | Aβ1-42         | Aβ1-42 Plus GPE3 |
|-----------|----------------|-----------------|
| ACADVL    | −0.71 ± 0.05   | 5.65 ± 1.25     |
| ADM2      | −0.38 ± 0.12   | 2.90 ± 0.28     |
| AKT1      | 0.15 ± 0.02    | 0.09 ± 0.03     |
| BCL2      | −0.86 ± 0.07   | 0.34 ± 0.01     |
| BCL2L1    | −0.91 ± 0.11   | 0.72 ± 0.03     |
| BRCA1     | −0.18 ± 0.02   | 6.92 ± 0.48     |
| CASP8     | 3.27 ± 0.21    | 0.29 ± 0.02     |
| CASP9     | 2.87 ± 0.35    | 0.54 ± 0.05     |
| CYP2D6    | −0.22 ± 0.21   | 3.94 ± 0.16     |
| DNAJ89    | −0.83 ± 0.18   | 16.95 ± 1.80    |
| FASLG     | 0.94 ± 0.04    | 0.35 ± 0.03     |
| HMOX1     | −0.47 ± 0.12   | 8.95 ± 1.55     |
| HSPA1A    | 3.80 ± 0.21    | 1.15 ± 0.45     |
| METAP2    | −0.66 ± 0.03   | 3.35 ± 0.90     |
| MK167     | −0.26 ± 0.01   | 3.20 ± 0.84     |
| NQO1      | −0.65 ± 0.06   | 5.66 ± 1.02     |
| SLC7A11   | −0.33 ± 0.02   | 6.96 ± 2.05     |
| UHRF1     | −0.81 ± 0.05   | 8.55 ± 1.60     |

The results of the PCR array indicated that Aβ1-42 caused remarkable increases in the CASP8, CASP9, and FASLG expressions. Again, a slight increase of AKT1 expression was observed after Aβ1-42 exposure. On the contrary, Aβ1-42 caused significant decreases in the levels of BCL2 and BCL2L1 genes. In parallel to these findings, Aβ- induced neuronal apoptosis resulted from increased CASP8 activation [46]. And a previous study determined that Aβ (as Aβ1-42 and Aβ25-35) weakly activated AKT1 in the SH-SY5Y neuroblastoma cell line [47]. On the other hand, BCL2 and BCL2L1, anti-apoptotic genes, were reported to down-regulated by applying Aβ1-42 in cultured rat hippocampal neurons and humans IMR-32 neuroblastoma cell line [48]. Besides, FASLG expression was significantly increased in senile plaques and neuro-filament-positive dystrophic neuritis, and relation to caspase
activation and neuritic apoptosis in AD brain [49]. The present results also proved that treatment with GPE3 alone did not lead to significant expressional alterations on apoptosis or necrosis-related genes. However, GPE3 modulated the expressional alteration of specific genes involving AKT1, BCL2, BCL2L, CASP8, CASP9, and FASLG genes by \( \beta \)-\( 1-42 \), and it was concluded that GPE related neuroprotection via anti-apoptotic and anti-necrotic effectiveness is based on the expression profiling of these genes.

It was revealed that the elevation of BRCA1 is a part of GPE3 related in vitro neuroprotection against neurotoxicity of \( \beta \). Again, \( \beta \)-\( 1-42 \) led to a significant increase in DNAJB1 and HSPA1A activities. In parallel to the present results, the expressions of DNAJB1 and HSPA1A genes were detected as up-regulated in patients with AD [50,51]. The present findings also revealed that GPE3 modulated the expression change of the gene HSPA1A induced by \( \beta \), and reduction of HSPA1A contributed to GPE3 related in vitro neuroprotection against neurotoxicity of \( \beta \). \( \beta \)-\( 1-42 \) also suppressed the expression of HMOX1, NQO1, and SLC7A11 activities. Following present findings, pharmacological induction or genetic over-expression of HMOX1 significantly ameliorated the neurotoxic effects of \( \beta \)-\( 1-42 \) in SH-SY5Y cells [52]. Likewise, free radical scavengers stimulated the Nrf2-dependent defensive gene NQO1 in SH-SY5Y cells [53]. Contrary to present findings, microarray analysis determined the up-regulation of SLC7A11 in patients with AD [54]. GPE3 treatment alone only provided a small contribution to HMOX1 (0.68-fold change). Moreover, GPE3 modulated the expressions of the gene HMOX1, NQO1, and SLC7A11 induced by \( \beta \)-\( 1-42 \). Consequently, the elevation of reduced HMOX1, NQO1, and SLC7A11 expressions were conferred as a backdrop of antioxidative protection by GPE3.

The results of RT² PCR array established that \( \beta \)-\( 1-42 \) significantly reduced the expressions of ADM2, DNAJB9, and UHRF1 genes. Consonant with these obtained results, the downregulation of the ADM2 gene was observed in neural progenitor cells (NPCs) derived from familial AD mutant PSEN1 subjects [55]. DNAJB9 suppressed the early stages of \( \beta \)-\( 1-42 \) aggregation in vitro. UHRF1 was thought to be responsible for controlling cellular proliferation and differentiation under physiological conditions [56]. The present data also showed that treatment with GPE3 alone did not lead to any statistically significant (\( p > 0.05 \)) expressional change of these genes. Further, GPE3 elevated the expressional change of the genes involving ADM2, DNAJB9, and UHRF1 reduced by \( \beta \)-\( 1-42 \). Thus, it was concluded that remarkable enhancement of ADM2, DNAJB9, and UHRF1 made a significant contribution GPE3-stimulated in vitro neuroprotection against \( \beta \) toxicity.

The experiences from animal studies suggested strong relationships between AD-associated abnormalities and brain fatty acid metabolism. AD-related pathologies inhibited homeostatic and regenerative functions of neural stem cells via perturbation of fatty acid metabolism [57]. The ACADM gene is responsible for producing medium-chain acyl-CoA dehydrogenase (MCAD) enzyme. Similarly, ACADVL is accountable for producing a very long-chain acyl-CoA dehydrogenase (VLCAD) enzyme. Both enzymes play a critical function in mitochondria. They are essential for fatty acid oxidation, which is the multistage procedure that metabolizes fats to energy. Additionally, ACOX1 gene coded peroxisomal straight-chain acyl-CoA oxidase enzyme, and this enzyme also has a function in \( \beta \)-oxidation [58]. The PCR array analysis indicates that \( \beta \)-\( 1-42 \) significantly decrease ACADM and ACADVL gene expressions. GPE3 modulated the expression changes of ACADVL gene altered by \( \beta \)-\( 1-42 \).

\( \beta \)-\( 1-42 \) led to decreases in METAP2 and MK167 activities. METAP2 is a cytoplasmic enzyme responsible for promoting cell proliferation and it was found in higher levels in SH-SY5Y neuroblastoma cells. MK167 is a reliable marker for assessing cell proliferation. It is involved in the pathogenesis of neurofibrillary degeneration in AD. Furthermore, GPE3 elevated the METAP2 and MK167 expressions that were reduced by \( \beta \)-\( 1-42 \). It was concluded that GPE3 also protected against the neurotoxicity of \( \beta \) by immune-related pathway. The molecular genetic analysis indicated that \( \beta \)-\( 1-42 \) treatment would reduce only CYP2D6 gene expression and GPE3 would modulate changes in gene expression of
CYP2D6 altered by Aβ1-42. CYP2D6 was shown to produce a toxin-metabolizing enzyme in SH-SY5Y cells and inactivates several neurotoxic substances.

4. Conclusions

Herein, we developed novel anti-Alzheimer formulations, based on GPE1, GPE2, and GPE3. The present in vitro results firstly suggested that treatments with novel GPE analogs might be promising for treating or preventing AD. Their multimodal action potential could modulate oxidative stress, ACh depletion, α-secretase inactivation, apoptotic and necrotic cell death as well as immunosuppression, the principal hallmarks of AD. Taking together all these multiple activities associated with pathological conditions of AD, the present novel GPEs seem to be potential multifunctional candidate for further experimental works to develop new anti-Alzheimer agents. These experiments should be performed on AD animal models to get a more logical result to understand the main keys behind the neuroprotective mechanisms of GPE derivatives. Moreover, β-amyloid peptide fibrilization analyses can be performed to obtain supporting information from the aspect of time dependent toxicity to strengthen the knowledge regarding the mechanism behind neuroprotective properties of GPE1, GPE2, and GPE3 tripeptides.

Supplementary Materials: The following are available online at https://www.mdpi.com/2218-273X/11/1/126/s1, Figure S1: The effects of GPE, MEM, GPE1, GPE2 and GPE3 on cell viability rates in differentiated SHSY5Y cells (MTT assay; % Cell viability). Symbol (*) represents statistically significant (p < 0.05) decreasing cell viability as compared to negative control (control-) group, Figure S2: The effects of GPE, MEM, GPE1, GPE2 and GPE3 on cell viability rates in differentiated SHSY5Y cells (LDH assay; % Cell viability). Symbol (*) represents statistically significant (p < 0.05) decrease in cell viability as compared to negative control (control-) group.

Author Contributions: Conceptualization, H.T., I.C., A.D.S. and A.M.; methodology, L.M., E.F., M.E.A., K.C., C.Y.K. and A.T.; software, H.T., A.D.S., I.C. and O.C.; validation, A.H., E.F., L.M., G.D.B. and A.T.; formal analysis, H.T., I.C., A.D.S. and A.T.; investigation, H.T., A.M., M.E.A., L.M., E.F. and G.D.B.; resources, H.T. and A.M.; data curation, A.H., G.D.B., C.Y.K., K.C. and O.C.; writing—original draft preparation, H.T., M.E.A., A.D.S. and I.C.; writing—review and editing, H.T., A.M. and L.M., visualization, A.T., A.H. and I.C.; supervision, A.D.S.; project administration, H.T. and I.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on request from the corresponding authors.

Acknowledgments: The authors are grateful to Gökhan Yüksel for improving the linguistic quality of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Yamamoto, H.; Murphy, L.J. Enzymatic conversion of IGF-I to des(1–3)IGF-I in rat serum and tissues: A further potential site of growth hormone regulation of IGF-I action. *J. Endocrinol.* 1995, 146, 141–148. [CrossRef] [PubMed]
2. Sara, V.R.; Carlsson-Skwirut, C.; Bergman, T.; Jörnvall, H.; Roberts, P.J.; Crawford, M.; Håkansson, L.N.; Civalero, I.; Nordberg, A. Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. *Biochem. Biophys. Res. Commun.* 1989, 165, 766–771. [CrossRef]
3. Burgos-Ramos, E.; Martos-Moreno, G.Á.; López, M.G.; Herranz, R.; Aguado-Llera, D.; Egea, J. The N-terminal tripeptide of insulin-like growth factor-I protects against β-amyloid-induced somatostatin depletion by calcium and glycogen synthase kinase 3β modulation. *J. Neurochem.* 2009, 109, 360–370. [CrossRef] [PubMed]
4. Sizonenko, S.V.; Sirimanne, E.S.; Williams, C.E.; Gluckman, P.D. Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic–ischemic injury. *Brain Res.* 2001, 922, 42–50. [CrossRef]
16. Turkez, H.; Cacciatore, I.; Arslan, M.E.; Tozlu, O.O.; Sönmez, E.; Mardinoglu, A. Neuroprotective effects of boron nitride nanoparticles in the experimental Parkinson’s disease model against MPP+ induced apoptosis. *Metab. Brain Dis.* **2020**, *35*, 947–957. [CrossRef]  
17. Kucinska, M.; Giron, M.D.; Piotrowska, H.; Lisiak, N.; Granig, W.H.; Lopez-Jaramillo, F.J. Novel promising estrogenic receptor analogues of Gly-l-Pro-l-Glu (GPE) as neuroprotective agents. *Bioorg. Med. Chem. Lett.* **2019**, *29*, 1392–1396. [CrossRef] [PubMed]  
18. Chang, S.; Shan, X.; Li, X.; Fan, W.; Zhang, S.Q.; Zhang, J. Toxoplasma gondii rhoptry protein ROP16 mediates partially SH-SY5Y cell apoptosis and cell cycle arrest by directing ser15/37 phosphorylation of p53. *Int. J. Biol. Sci.* **2015**, *11*, 1215–1225. [CrossRef] [PubMed]  
19. Alonso De Diego, S.A.; Gutiérrez-Rodriguez, M.; Pérez De Vega, M.J.; Casabona, D.; Cativiela, C.; González-Muñiz, R. New Gly-Pro-Glu (GPE) analogues: Expedite solid-phase synthesis and biological activity. *Bioorganic Med. Chem. Lett.* **2006**, *16*, 1392–1396. [CrossRef] [PubMed]  
20. Encinas, M.; Iglesias, M.; Liu, Y.; Wang, H.; Muahisen, A.; Çerda, V. Sequential Treatment of SH-SY5Y Cells with Retinoic Acid and Brain-Derived Neurotrophic Factor Gives Rise to Fully Differeniated, Neurotrophic Factor-Dependent, Human Neuron-Like Cells. *J. Neurochem.* **2002**, *79*, 379–387. [CrossRef]  
21. Emsen, B.; Aslan, A.; Toprak, B.; Turkez, H. In vitro antitumor activities of the lichen compounds olivetoric, physodic and psoromic acid in rat neuron and glioblastoma cells. *Pharm. Biol.* **2016**, *54*, 1748–1762. [CrossRef]  
22. Alak, G.; Özgeris, F.B.; Yeltekin, A.C.; Parlak, V.; Ucar, A.; Caglar, O. Hematological and Hepatic Effects of Ulexite in Zebrafish. *Environ. Toxicol. Pharmacol.* **2020**, *80*, 103496. [CrossRef]  
23. Kucinska, M.; Giron, M.D.; Piotrowska, H.; Lisiak, N.; Granig, W.H.; Lopez-Jaramillo, F.J. Novel promising estrogenic receptor modulators: Cytotoxic and estrogenic activity of benzaldehydes and dihydrobenzaldehydes. *PLoS ONE* **2016**, *11*, e0145615. [CrossRef]  
24. Guan, J.; George, S. Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1 glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic–ischemic adult rats. *Neuropharmacology* **2004**, *47*, 892–903. [CrossRef] [PubMed]  
25. Guan, J.; Thomas, G.B.; Lin, H.; Mathai, S.; Bachelor, D.C.; George, S. Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1 glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic–ischemic adult rats. *Neuropharmacology* **2004**, *47*, 892–903. [CrossRef] [PubMed]  
26. Agudo-Llera, D.; Martín-Martínez, M.; García-López, M.T.; Arilla-Ferreiro, E.; Barrios, V. Gly-Pro-Glu protects β-amyloid-induced somatostatin depletion in the rat cortex. *Neuroreport* **2004**, *15*, 1799–1982. [CrossRef]  
27. Minelli, A.; Conte, C.; Cacciatore, I.; Cornacchia, C.; Pinnen, F. Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to l-dopa in a Parkinson’s animal model. *Amino Acids* **2012**, *43*, 1359–1367. [CrossRef]  
28. Turkez, H.; Togar, B.; Tatar, A.; Geyikoglu, F.; Hacımuftuoglu, A. Cytotoxic and cytogenetic effects of n-Mart β-lactam on human cancer cells. *Cancer Cell Int.* **2013**, *13*, 12. [CrossRef] [PubMed]  
29. Hu, W.; Gray, N.W.; Brimijoin, S. Amyloid-beta increases acetylcholinesterase expression in neuroblastoma cells by reducing enzyme degradation. *J. Neurochem.* **2004**, *86*, 470–478. [CrossRef]  
30. Nilsson-Hakansson, L.; Civalero, I.; Zhang, X.; Carlsson-Skwirut, C.; Sara, V.R.; Nordberg, A. Effects of IGF-1, truncated IGF-1 and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain. *Neuroreport* **1993**, *4*, 1111–1114.
31. Mori, T.; Koyama, N.; Yokoo, T.; Segawa, T.; Maeda, M.; Sawmiller, D. Gallic acid is a dual α/β-secretase modulator that reverses cognitive impairment and remedies pathology in Alzheimer mice. *J. Biol. Chem.* 2020, 295, 16251–16266. [CrossRef] [PubMed]

32. Sennvik, K.; Fastbom, J.; Blomberg, M.; Wahlund, L.-O.; Winblad, B.; Benedíkz, E. Levels of α- and β-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer’s disease patients. *Neurosci. Lett.* 2000, 278, 169–172. [CrossRef]

33. Famer, D.; Crisby, M. Rosuvastatin reduces caspase-3 activity and up-regulates α-secretase in human neuroblastoma SH-SY5Y cells exposed to Aβ. *Neurosci. Lett.* 2004, 371, 209–214. [CrossRef] [PubMed]

34. Vingtdeux, V.; Marambaud, P. Identification and biology of β-secretase. *J. Neurochem.* 2012, 120, 34–45. [CrossRef]

35. Evin, G.; Hince, C. BACE1 as a Therapeutic Target in Alzheimer’s Disease: Rationale and Current Status. *Drugs Aging* 2013, 30, 755–764. [CrossRef]

36. Banerjee, P.; Sahoo, A.; Anand, S.; Ganguly, A.; Righi, G.; Bovicelli, P. Multiple Mechanisms of Iron-Induced Amyloid Beta-Peptide Accumulation in SH-SY5Y Cells: Protective Action of Negelein. *Neuromol. Med.* 2014, 16, 787–798. [CrossRef]

37. Yamamori, H.; Tanaka, T.; Kudo, T.; Takeda, M. Amyloid-beta down-regulates XIAP expression in human SH-SY5Y neuroblastoma cells. *Neuroreport* 2004, 15, 851–854. [CrossRef]

38. Butterfield, D.A.; Boyd-Kimball, D. Amyloid β-Peptide(1-42) Contributes to the Oxidative Stress and Neurodegeneration Found in Alzheimer Disease Brain. *Brain Pathol.* 2006, 14, 426–432. [CrossRef]

39. Cioanca, O.; Hritcu, L.; Mihasan, M.; Trifan, A.; Hancianu, M. Inhalation of coriander volatile oil increased anxiolytic—antidepressant-like behaviors and decreased oxidative status in beta-amyloid (1-42) rat model of Alzheimer’s disease. *Physiol. Behav.* 2014, 131, 67–74. [CrossRef]

40. Yu, L.; Wang, S.; Chen, X.; Yang, H.; Li, X.; Xu, Y. Orientin alleviates cognitive deficits and oxidative stress in Aβ1–42-induced mouse model of Alzheimer’s disease. *Life Sci.* 2015, 121, 104–109. [CrossRef]

41. Hacioglu, C.; Kar, F.; Kar, E.; Kara, Y.; Kanbak, G. Effects of Curcumin and Boric Acid Against Neurodegenerative Damage Induced by Amyloid Beta (1–42). *Biol. Trace Elem. Res.* 2020. [CrossRef] [PubMed]

42. Saeed, K.; Shah, S.A.; Ullah, R.; Alam, S.I.; Park, J.S.; Saleem, S. Quinovic Acid Impedes Cholesterol Dyshomeostasis, Oxidative Stress, and Neurodegeneration in an Amyloid-β-Mediated Mouse Model. *Oxid. Med. Cell Longev.* 2020, 2020, 1–20. [CrossRef] [PubMed]

43. Golde, T.E. The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease. *Mol. Neurodegener.* 2009, 4, 8. [CrossRef]

44. Sutton, E.T.; Hellermann, G.R.; Thomas, T. β-Amyloid-induced endothelial necrosis and inhibition of nitric oxide production. *Exp. Cell Res.* 1997, 230, 368–376. [CrossRef] [PubMed]

45. Cacciatore, I.; Fornasari, E.; Marinelli, L.; Eusepi, P.; Ciulla, M.; Ozdemir, O. Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma. *Eur. J. Pharm. Sci.* 2017, 109, 402–411. [CrossRef]

46. Ivins, K.J.; Thornton, P.L.; Rohn, T.T.; Cotman, C.W. Neuronal Apoptosis Induced by β-Amyloid Is Mediated by Caspase-8. *Neurobiol. Dis.* 1999, 6, 440–449. [CrossRef]

47. Wei, W.; Wang, X.; Kusiak, J.W. Signaling events in amyloid β-peptide-induced neuronal death and insulin-like growth factor I protection. *J. Biol. Chem.* 2002, 277, 17649–17656. [CrossRef]

48. Pike, C.J. Estrogen Modulates Neuronal Bcl-xl Expression and β-Amyloid-Induced Apoptosis. *J. Neurochem.* 2001, 72, 1552–1563. [CrossRef]

49. Su, J.H.; Anderson, A.J.; Cribs, D.H.; Tu, C.; Tong, L.; Kesslack, P. Fas and Fas Ligand are associated with neurotic degeneration in the AD brain and participate in α-amyloid-induced neuronal death. *Neurobiol. Dis.* 2003, 12, 182–193. [CrossRef]

50. Clarimón, J.; Bertranpetit, J.; Boada, M.; Tarraga, L.; Comas, D. HSP70-2 (HSPA1B) is Associated with Noncognitive Symptoms in Late-Onset Alzheimer’s Disease. *J. Geriatr. Psychiatr. Neurol.* 2003, 16, 146–150. [CrossRef]

51. Chi, L.-M.; Wang, X.; Nan, G.-X. In silico analyses for molecular genetic mechanism and candidate genes in patients with Alzheimer’s disease. *Acta Neurol. Belg.* 2016, 116, 543–547. [CrossRef] [PubMed]

52. Hettiarachchi, N.; Dallas, M.; Al-Owais, M.; Griffiths, H.; Hooper, N.; Scrapp, J. Heme oxygenase-1 protects against Alzheimer’s amyloid-β1–42-induced toxicity via carbon monoxide production. *Cell Death Dis.* 2014, 5, e1569. [CrossRef] [PubMed]

53. Simon, E.; Serafini, M.M.; Caporaso, R.; Marchetti, C.; Racchi, M.; Minarini, A. Targeting the Nrf2/Amyloid-Beta Liaison in Alzheimer’s Disease: A Rational Approach. *ACS Chem. Neurosci.* 2017, 8, 1618–1627. [CrossRef] [PubMed]

54. Zhao, J.; Li, L.; Leissring, M.A. Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. *Mol. Neurodegener.* 2009, 4, 4. [CrossRef]

55. Ribatti, D.; Ponzoni, M. Antiangiogenic strategies in neuroblastoma. *Cancer Treat Rev.* 2005, 31, 27–34. [CrossRef]

56. Mann, A.; Tyndall, R.F. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. *Eur. J. Neurosci.* 2011, 33, 1185–1193. [CrossRef]

57. Koliassinova, K.N.; Povarnina, P.Y.; Tallerova, A.V.; Firsova, Y.N.; Nikolaev, S.V.; Antipova, T.A. Glyproline Pro-Ampakine with Neuroprotective Activity. *Neuroprotection—New Approaches Prospect IntechOpen* 2020. [CrossRef]

58. Jameson, E.; Walter, J.H. Medium-chain acyl-CoA dehydrogenase deficiency. *Paediatr. Child Health* 2019, 29, 123–126. [CrossRef]